FDA BRIEF: Week of July 11, 2016

Neurological Devices: Classification of Thermal System for Insomnia

Product : Cereve Sleep System
Classification: Class II special controls.
Codification: 21 CFR 882.5700
Risks and Mitigations:
Table 1--Thermal System for Insomnia Risks and Mitigation Measures
------------------------------------------------------------------------
Identified risk Mitigation method
------------------------------------------------------------------------
Adverse skin reaction.................. Biocompatibility Assessment.
Labeling.
Electromagnetic Interference with Other Electromagnetic Compatibility
Devices. Testing.
Labeling.
Electrical Safety (e.g., shock)........ Electrical Safety Testing.
Labeling.
Thermal Injury......................... Non-clinical Performance
Testing.
Software Verification,
Validation, and Hazard
Analysis.
Labeling.
------------------------------------------------------------------------
Gastroenterology-Urology Devices: Metallic Biliary Stent System for Benign Strictures

Product : WallFlex Biliary Rx Fully Covered Stent System
Classification: Class II special controls.
Codification: 21 CFR 876.5011
Risks and Mitigations:
Table 1--Metallic Biliary Stent System for Benign Strictures Risks and
Mitigation Measures
------------------------------------------------------------------------
Identified risk Mitigation measure
------------------------------------------------------------------------
Adverse tissue reaction................ Biocompatibility Evaluation.
Labeling.
Infection.............................. Sterilization Validation.
Shelf Life Validation.
Labeling.
Bile duct obstruction.................. Clinical Performance Testing.
Stent migration...................... Non-clinical Performance
Testing.
Stent does not resolve obstruction... Shelf Life Validation.
Stent cannot be placed............... Labeling.
Expansion/compression forces.
Foreshortening.......................
Trauma to bile ducts................... Clinical Performance Testing.
[[Page 45231]]
During stent deployment.............. Non-clinical Performance
Testing.
During removal....................... Shelf Life Validation.
Due to stent migration............... Labeling.
During stent indwell.
Inability to safely remove stent.....
Expansion/compression forces.........
------------------------------------------------------------------------